Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Lung Cancer

Free Subscription Articles published in J Thorac Cardiovasc Surg Retrieve available abstracts of 223 articles: HTML format

Single Articles

April 2024
1. ODEH AM, Perez-Tamayo RA, Abdelsattar ZM
   A wedge is still better than stereotactic body radiation therapy in the national cancer database.
   J Thorac Cardiovasc Surg. 2024;167:e100-e101.
   PubMed    
   
   
   
2. KIM AT, Ding L, Lee HB, Ashbrook MJ, et al
   Longer hospitalizations, more complications, and greater readmissions for patients with comorbid psychiatric disorders undergoing pulmonary lobectomy.
   J Thorac Cardiovasc Surg. 2024;167:1502-1511.
   PubMed     Abstract available
   
   
   March 2024
3. RUSCH VW
   Commentary: "Real world" neoadjuvant immunochemotherapy for lung cancer:Additional data but still many questions.
   J Thorac Cardiovasc Surg. 2024 Mar 14:S0022-5223(24)00209.
   PubMed    
   
   
   
4. KRISTENSON K, Hedman K
   Percent predicted peak oxygen uptake is superior to weight-indexed peak oxygen uptake in risk stratification before lung cancer lobectomy.
   J Thorac Cardiovasc Surg. 2024 Mar 5:S0022-5223(24)00187.
   PubMed     Abstract available
   
   
   
5. 
   Discussion to: AATS 2023: Empiric flap coverage for the pneumonectomy stump: How protective is it? A single-institution cohort study.
   J Thorac Cardiovasc Surg. 2024;167:859-860.
   PubMed    
   
   
   
6. 
   Discussion to: Extent of surgical resection for radiologically subsolid T1N0 invasive lung adenocarcinoma: When is a wedge resection acceptable?
   J Thorac Cardiovasc Surg. 2024;167:810-811.
   PubMed    
   
   
   
7. STEIMER D, Coughlin JM, Yates E, Xie Y, et al
   Empiric flap coverage for the pneumonectomy stump: How protective is it? A single-institution cohort study.
   J Thorac Cardiovasc Surg. 2024;167:849-858.
   PubMed     Abstract available
   
   
   
8. SACHDEVA UM
   Commentary: The genes stand alone: Genetic risk factors predict early pulmonary recurrence of colorectal carcinoma metastases.
   J Thorac Cardiovasc Surg. 2024;167:820-821.
   PubMed    
   
   
   
9. DEBOEVER N, Bayley EM, Eisenberg MA, Hofstetter WL, et al
   Lung surveillance following colorectal cancer pulmonary metastasectomy: Utilization of clinicopathologic risk factors to guide strategy.
   J Thorac Cardiovasc Surg. 2024;167:814-819.
   PubMed     Abstract available
   
   
   
10. ZHANG C, Pan Y, Li H, Zhang Y, et al
    Extent of surgical resection for radiologically subsolid T1N0 invasive lung adenocarcinoma: When is a wedge resection acceptable?
    J Thorac Cardiovasc Surg. 2024;167:797-809.
    PubMed     Abstract available
    
    
    February 2024
11. COOPER A, Chaft JE, Bott MJ
    Induction Therapy for Non-Small Cell Lung Cancer.
    J Thorac Cardiovasc Surg. 2024 Feb 12:S0022-5223(24)00160.
    PubMed    
    
    
    
12. 
    Discussion to: Surgical outcomes after chemotherapy plus nivolumab and chemotherapy plus nivolumab and ipilimumab in patients with non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2024 Feb 10:S0022-5223(24)00022.
    PubMed    
    
    
    
13. KOREVAAR DA, Annema JT
    Targeted versus systematic nodal staging in early-stage lung cancer.
    J Thorac Cardiovasc Surg. 2024 Feb 8:S0022-5223(24)00004.
    PubMed    
    
    
    
14. CALL S, Reig-Oussedik N, Obiols C, Sanz-Santos J, et al
    Video-assisted mediastinoscopic lymphadenectomy (VAMLA): mature results for staging non-small cell lung cancer with normal mediastinum.
    J Thorac Cardiovasc Surg. 2024 Feb 2:S0022-5223(24)00098.
    PubMed     Abstract available
    
    
    
15. ZHANG X, Tsauo J, Tian P, Zhao L, et al
    Randomized comparison of the four-hook anchor device and hook-wire use for the preoperative localization of pulmonary nodules.
    J Thorac Cardiovasc Surg. 2024;167:498-507.
    PubMed     Abstract available
    
    
    January 2024
16. 
    Discussion to: National enrollment of lung cancer clinical trials is disproportionate based on race and health care access.
    J Thorac Cardiovasc Surg. 2024 Jan 27:S0022-5223(23)01209.
    PubMed    
    
    
    
17. MARTIN TK, Dinerman A, Sudhaman S, Budde G, et al
    Early real-world experience monitoring circulating tumor DNA in resected early-stage non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2024 Jan 18:S0022-5223(24)00075.
    PubMed     Abstract available
    
    
    
18. FUKUI M, Matsunaga T, Hattori A, Takamochi K, et al
    Prognostic significance of preoperative exercise tolerance in patients with early-stage lung cancer.
    J Thorac Cardiovasc Surg. 2024 Jan 11:S0022-5223(24)00006.
    PubMed     Abstract available
    
    
    
19. LIN N, Berry MF
    Commentary: Re-consult surgery for lung cancer patients? The role of resection after initial non-operative therapy.
    J Thorac Cardiovasc Surg. 2024 Jan 9:S0022-5223(24)00007.
    PubMed    
    
    
    
20. TOHMASI S, Puri V
    Commentary: Segmentectomy versus lobectomy: Are the findings of the JCOG 0802 and CALGB 140503 trials generalizable to the US population?
    J Thorac Cardiovasc Surg. 2024;167:365-366.
    PubMed    
    
    
    
21. POTTER AL, Kim J, McCarthy ML, Senthil P, et al
    Segmentectomy versus lobectomy in the United States: Outcomes after resection for first primary lung cancer and treatment patterns for second primary lung cancers.
    J Thorac Cardiovasc Surg. 2024;167:350-364.
    PubMed     Abstract available
    
    
    December 2023
22. 
    Discussion to: Preoperative predictors of spread through air spaces in lung cancer.
    J Thorac Cardiovasc Surg. 2023 Dec 27:S0022-5223(23)01119.
    PubMed    
    
    
    
23. 
    Discussion to: Lung resection after initial nonoperative treatment for non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2023 Dec 27:S0022-5223(23)01129.
    PubMed    
    
    
    
24. KWAK M, Bassiri A, Jiang B, Sinopoli J, et al
    National enrollment of lung cancer clinical trials is disproportionate based on race and health care access.
    J Thorac Cardiovasc Surg. 2023 Dec 18:S0022-5223(23)01199.
    PubMed     Abstract available
    
    
    
25. SAKOWITZ S, Bakhtiyar SS, Curry J, Ali K, et al
    Association of Neighborhood Socioeconomic Disadvantage with Utilization of Minimally Invasive Resection for Non-Small Cell Lung Cancer.
    J Thorac Cardiovasc Surg. 2023 Dec 13:S0022-5223(23)01195.
    PubMed     Abstract available
    
    
    
26. DONINGTON J, Hu X, Zhang S, Song Y, et al
    Event-Free Survival as a Predictor of Overall Survival and Recurrence Burden of Patients with Non-Small Cell Lung Cancer Receiving Neoadjuvant Therapy.
    J Thorac Cardiovasc Surg. 2023 Dec 11:S0022-5223(23)01193.
    PubMed     Abstract available
    
    
    
27. SERVAIS EL
    Commentary: Utilization and equity in lung cancer screening: time to abandon the one-size-fits-all approach?
    J Thorac Cardiovasc Surg. 2023 Dec 4:S0022-5223(23)01122.
    PubMed    
    
    
    
28. 
    Discussion to: Superior sulcus non-small cell lung cancers (Pancoast tumors): Current outcomes after multidisciplinary management.
    J Thorac Cardiovasc Surg. 2023;166:1488-1489.
    PubMed    
    
    
    
29. MCLAUGHLIN K, Tan KS, Dycoco J, Chen MF, et al
    Superior sulcus non-small cell lung cancers (Pancoast tumors): Current outcomes after multidisciplinary management.
    J Thorac Cardiovasc Surg. 2023;166:1477-1487.
    PubMed     Abstract available
    
    
    
30. CAO H, Ma Z, Li Y, Zhang Y, et al
    Prognostic value of KRAS G12C mutation in lung adenocarcinoma stratified by stages and radiological features.
    J Thorac Cardiovasc Surg. 2023;166:e479-e499.
    PubMed     Abstract available
    
    
    
31. SARKARIA IS, Martin LW, Rice DC, Blackmon SH, et al
    Pafolacianine for intraoperative molecular imaging of cancer in the lung: The ELUCIDATE trial.
    J Thorac Cardiovasc Surg. 2023;166:e468-e478.
    PubMed     Abstract available
    
    
    November 2023
32. DUNNE EG, Fick CN, Tan KS, Toumbacaris N, et al
    Lung Resection After Initial Nonoperative Treatment for Non-Small Cell Lung Cancer.
    J Thorac Cardiovasc Surg. 2023 Nov 30:S0022-5223(23)01116.
    PubMed     Abstract available
    
    
    
33. 
    Discussion to: Induction chemoimmunotherapy with surgery versus concurrent chemoradiation followed by immunotherapy for stage III-N2 non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2023 Nov 28:S0022-5223(23)00992.
    PubMed    
    
    
    
34. TASNIM S, Raja S, Mukhopadhyay S, Blackstone EH, et al
    Preoperative Predictors of Spread Through Air Spaces (STAS) in Lung Cancer.
    J Thorac Cardiovasc Surg. 2023 Nov 23:S0022-5223(23)01106.
    PubMed     Abstract available
    
    
    
35. MANIWA T, Okami J, Miyoshi T, Wakabayashi M, et al
    Lymph node dissection in small peripheral lung cancer: supplemental analysis of JCOG0802/WJOG4607L.
    J Thorac Cardiovasc Surg. 2023 Nov 22:S0022-5223(23)01099.
    PubMed     Abstract available
    
    
    
36. DYAS AR, Bronsert MR, Stuart CM, Thomas MB, et al
    Analyzing the Impact of the COVID-19 Pandemic on Initial Oncologic Presentation and Treatment of Non-Small Cell Lung Cancer in the United States.
    J Thorac Cardiovasc Surg. 2023 Nov 17:S0022-5223(23)01098.
    PubMed     Abstract available
    
    
    
37. SULLIVAN KA, Farrokhyar F, Patel YS, Liberman M, et al
    Preoperative Mediastinal Staging in Early-Stage Lung Cancer: Targeted Nodal Sampling is Not Inferior to Systematic Nodal Sampling.
    J Thorac Cardiovasc Surg. 2023 Nov 17:S0022-5223(23)01096.
    PubMed     Abstract available
    
    
    
38. 
    Discussion to: Association of socioeconomic factors with the receipt of neoadjuvant therapy for patients with non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2023 Nov 17:S0022-5223(23)00979.
    PubMed    
    
    
    
39. 
    Discussion to AATS 2023: Exposure to Agent Orange is associated with increased recurrence after surgical treatment of stage I non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2023 Nov 9:S0022-5223(23)00904.
    PubMed    
    
    
    
40. AL-THANI S, Nasar A, Villena-Vargas J, Chow O, et al
    Should Sampling of Three N2 Stations be a Quality Metric for Curative Resection of Stage I Lung Cancer?
    J Thorac Cardiovasc Surg. 2023 Nov 3:S0022-5223(23)01015.
    PubMed     Abstract available
    
    
    
41. SEPESI B, Mehran R, Spicer J, Cascone T, et al
    Neostar Trial and The Current Status of Neoadjuvant Therapy in Non-Small Cell Lung Cancer.
    J Thorac Cardiovasc Surg. 2023 Nov 1:S0022-5223(23)01012.
    PubMed    
    
    
    October 2023
42. 
    Discussion to: Quality improvement mechanisms to improve lymph node staging for lung cancer: Trends from a statewide database.
    J Thorac Cardiovasc Surg. 2023 Oct 20:S0022-5223(23)00865.
    PubMed    
    
    
    
43. 
    Discussion to: Overall survival in low-comorbidity patients with stage I non-small cell lung cancer who chose stereotactic body radiotherapy compared to surgery.
    J Thorac Cardiovasc Surg. 2023 Oct 20:S0022-5223(23)00867.
    PubMed    
    
    
    
44. REDDY RM
    Commentary: Neoadjuvant Immunotherapy followed by Lung Cancer Resection: Is the Future Already Here?
    J Thorac Cardiovasc Surg. 2023 Oct 18:S0022-5223(23)00980.
    PubMed    
    
    
    
45. POTTER AL, Senthil P, Srinivasan D, Raman V, et al
    Persistent Racial and Sex-based Disparities in Lung Cancer Screening Eligibility.
    J Thorac Cardiovasc Surg. 2023 Oct 18:S0022-5223(23)00981.
    PubMed     Abstract available
    
    
    
46. WOLF AS
    Commentary: Nothing is free: Surgeons' and radiation oncologists' biases about treating early stage lung cancer in healthy patients.
    J Thorac Cardiovasc Surg. 2023 Oct 17:S0022-5223(23)00986.
    PubMed    
    
    
    
47. KAMTAM DN, Shrager JB
    We should be considering lung cancer screening for never-smoking Asian-American females.
    J Thorac Cardiovasc Surg. 2023 Oct 14:S0022-5223(23)00976.
    PubMed    
    
    
    
48. FELDMAN H, Sepesi B, Leung CH, Lin H, et al
    Surgical Outcomes After Chemotherapy plus Nivolumab and Chemotherapy plus Nivolumab and Ipilimumab in Patients with Non-Small Cell Lung Cancer.
    J Thorac Cardiovasc Surg. 2023 Oct 8:S0022-5223(23)00900.
    PubMed     Abstract available
    
    
    
49. YOSHINO I, Moriya Y, Suzuki K, Wakabayashi M, et al
    Long-term outcome of patients with peripheral ground-glass opacity-dominant lung cancer after sublobar resections.
    J Thorac Cardiovasc Surg. 2023;166:1222-1231.
    PubMed     Abstract available
    
    
    
50. STEIMER D, Ugalde Figueroa P
    Commentary: Sublobar resection for ground-glass opacity: Is less really more?
    J Thorac Cardiovasc Surg. 2023;166:1232-1233.
    PubMed    
    
    
    September 2023
51. 
    Discussion to: Perspectives, risk factors, and coping mechanisms in patients with self-reported financial burden following lung cancer surgery.
    J Thorac Cardiovasc Surg. 2023 Sep 30:S0022-5223(23)00783.
    PubMed    
    
    
    
52. ANTONOFF MB, Deboever N, Werner R, Altan M, et al
    Surgery for Oligometastatic Non-Small Cell Lung Cancer.
    J Thorac Cardiovasc Surg. 2023 Sep 29:S0022-5223(23)00874.
    PubMed     Abstract available
    
    
    
53. ELBAHRAWY MM, Kamel MK, Rodriguez-Quintero JH, Vimolratana M, et al
    Association of Socioeconomic Factors with the Receipt of Neoadjuvant Therapy for Patients with Non-Small Cell Lung Cancer.
    J Thorac Cardiovasc Surg. 2023 Sep 21:S0022-5223(23)00857.
    PubMed     Abstract available
    
    
    
54. KUMAR A, Srinivasan D, Potter A, Mathey-Andrews C, et al
    Induction Chemoimmunotherapy with Surgery versus Concurrent Chemoradiation followed by Immunotherapy for Stage III-N2 Non-small Cell Lung Cancer.
    J Thorac Cardiovasc Surg. 2023 Sep 16:S0022-5223(23)00853.
    PubMed     Abstract available
    
    
    
55. POTTER AL, Rosenstein AL, Kandala K, Venkateswaran S, et al
    Shortage of Thoracic Surgeons in the United States: Implications for Treatment and Survival for Stage I Lung Cancer Patients.
    J Thorac Cardiovasc Surg. 2023 Sep 14:S0022-5223(23)00796.
    PubMed     Abstract available
    
    
    
56. SUBRAMANIAN MP, Eaton DB Jr, Labilles UL, Heiden BT, et al
    Exposure to Agent Orange is Associated with Increased Recurrence after Surgical Treatment of Stage I Non-Small Cell Lung Cancer.
    J Thorac Cardiovasc Surg. 2023 Sep 12:S0022-5223(23)00788.
    PubMed     Abstract available
    
    
    
57. EISENBERG MA, Deboever N, Mills AC, Egyud MR, et al
    Impact of Travel Distance on Receipt of Indicated Adjuvant Therapy in Resected Non-Small Cell Lung Cancer.
    J Thorac Cardiovasc Surg. 2023 Sep 9:S0022-5223(23)00765.
    PubMed     Abstract available
    
    
    August 2023
58. SAKANE T, Nakajima K, Iwata H, Nakano T, et al
    Lobectomy Versus Proton Therapy for Stage I Non-small Cell Lung Cancer.
    J Thorac Cardiovasc Surg. 2023 Aug 23:S0022-5223(23)00741.
    PubMed     Abstract available
    
    
    
59. KALATA S, Reddy RM, Norton EC, Clark MJ, et al
    Quality Improvement Mechanisms to Improve Lymph Node Staging for Lung Cancer: Trends from a Statewide Database.
    J Thorac Cardiovasc Surg. 2023 Aug 23:S0022-5223(23)00744.
    PubMed     Abstract available
    
    
    
60. DEBOEVER N, Mitchell KG, Farooqi A, Ludmir EB, et al
    Perioperative and oncologic outcomes of pulmonary resection for synchronous oligometastatic non-small cell lung cancer: Evidence for surgery in advanced disease.
    J Thorac Cardiovasc Surg. 2023 Aug 21:S0022-5223(23)00735.
    PubMed     Abstract available
    
    
    
61. ALTORKI NK, Chow OS
    Cancer and Leukemia Group B 140503: Is it time to turn the page on Lung Cancer Study Group 821?
    J Thorac Cardiovasc Surg. 2023 Aug 18:S0022-5223(23)00725.
    PubMed    
    
    
    
62. D'ANDRILLI A, Maurizi G, Ciccone AM, Ibrahim M, et al
    RECONSTRUCTION OF THE HEART AND THE AORTA FOR RADICAL RESECTION OF LUNG CANCER.
    J Thorac Cardiovasc Surg. 2023 Aug 2:S0022-5223(23)00646.
    PubMed     Abstract available
    
    
    
63. ZHOU N, Bell CS, Feldman HA, Haymaker CL, et al
    Tumor thickness in mesothelioma predicts differential response to neoadjuvant therapy and survival.
    J Thorac Cardiovasc Surg. 2023;166:362-371.
    PubMed     Abstract available
    
    
    
64. RUSCH VW
    Commentary: Assessing tumor stage and treatment response in pleural mesothelioma: Are pleural thickness measurements the new standard?
    J Thorac Cardiovasc Surg. 2023;166:372-373.
    PubMed    
    
    
    
65. KAMEL MK, Kariyawasam S, Stiles B
    Overestimation of screening-related complications in the National Lung Screening Trial.
    J Thorac Cardiovasc Surg. 2023;166:336-344.
    PubMed     Abstract available
    
    
    July 2023
66. RUSCH VW
    Commentary: Lobectomy, segmentectomy or wedge resection for Stage IA lung cancer: Several choices, many questions.
    J Thorac Cardiovasc Surg. 2023 Jul 30:S0022-5223(23)00645.
    PubMed    
    
    
    
67. UDELSMAN BV, Canavan ME, Zhan PL, Ely S, et al
    Overall survival in low-comorbidity patients with stage I non-small cell lung cancer who chose stereotactic body radiotherapy compared to surgery.
    J Thorac Cardiovasc Surg. 2023 Jul 25:S0022-5223(23)00625.
    PubMed     Abstract available
    
    
    
68. ALTORKI N, Wang X, Damman B, Mentlick J, et al
    Lobectomy, segmentectomy or wedge resection for peripheral clinical T1aN0 non-small cell lung cancer: a post-hoc analysis of CALGB 140503 (Alliance).
    J Thorac Cardiovasc Surg. 2023 Jul 18:S0022-5223(23)00612.
    PubMed     Abstract available
    
    
    
69. D'AMICO TA
    The Video-Assisted Thoracoscopic or Open Lobectomy (VIOLET) trial: The final chapter to this epic.
    J Thorac Cardiovasc Surg. 2023;166:265-267.
    PubMed    
    
    
    
70. CONNOLLY JG, Kalchiem-Dekel O, Tan KS, Dycoco J, et al
    Feasibility of shape-sensing robotic-assisted bronchoscopy for biomarker identification in patients with thoracic malignancies.
    J Thorac Cardiovasc Surg. 2023;166:231-240.
    PubMed     Abstract available
    
    
    
71. HERRERA LJ, Schumacher LY, Hartwig MG, Bakhos CT, et al
    Pulmonary Open, Robotic, and Thoracoscopic Lobectomy study: Outcomes and risk factors of conversion during minimally invasive lobectomy.
    J Thorac Cardiovasc Surg. 2023;166:251-262.
    PubMed     Abstract available
    
    
    June 2023
72. DEBOEVER N, Eisenberg MA, Antonoff MB, Hofstetter WL, et al
    Perspectives, Risk Factors, and Coping Mechanisms in Patients with Self-Reported Financial Burden following Lung Cancer Surgery.
    J Thorac Cardiovasc Surg. 2023 Jun 23:S0022-5223(23)00533.
    PubMed     Abstract available
    
    
    
73. KAWAMOTO N, Mimae T, Tsutani Y, Kamigaichi A, et al
    Tumor distance from the mediastinum predicts N2 upstaging in clinical stage I lower-lobe non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2023 Jun 15:S0022-5223(23)00526.
    PubMed     Abstract available
    
    
    
74. KIDANE B, Bott M, Spicer J, Backhus L, et al
    The American Association for Thoracic Surgery (AATS) 2023 Expert Consensus Document: Staging and multidisciplinary management of patients with early-stage non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2023 Jun 9:S0022-5223(23)00363.
    PubMed     Abstract available
    
    
    
75. ISHIWATA T, Hiraishi Y, Bernards N, Sata Y, et al
    Transbronchial real-time lung tumor localization with folate receptor-targeted near-infrared molecular imaging: A proof of concept study in animal models.
    J Thorac Cardiovasc Surg. 2023;165:e240-e251.
    PubMed     Abstract available
    
    
    
76. EISENBERG MA, Hofstetter WL
    Commentary: Complexity in rare disease: A look at surgical outcomes in tracheobronchial adenoid cystic carcinoma.
    J Thorac Cardiovasc Surg. 2023;165:1965-1966.
    PubMed    
    
    
    
77. ELWYN G, Brunelli A
    Shared decision making and its relevance to thoracic surgery.
    J Thorac Cardiovasc Surg. 2023;165:1967-1970.
    PubMed    
    
    
    
78. BUDUHAN G, Chand E, Kidane B, Srinathan S, et al
    Impact of cost-awareness education and surgeon-led positive deviance on intraoperative costs of thoracoscopic lobectomy.
    J Thorac Cardiovasc Surg. 2023;165:1939-1946.
    PubMed     Abstract available
    
    
    
79. WEISS KD, Deeb AL, Wee JO, Swanson SJ, et al
    When a segmentectomy is not a segmentectomy: Quality assurance audit and evaluation of required elements for an anatomic segmentectomy.
    J Thorac Cardiovasc Surg. 2023;165:1919-1925.
    PubMed     Abstract available
    
    
    May 2023
80. RIPLEY RT, Holmes HM, Whitlock RS, Groth SS, et al
    Pleurectomy and decortication are associated with better survival for bicavitary cytoreductive surgery for mesothelioma compared with extrapleural pneumonectomy.
    J Thorac Cardiovasc Surg. 2023;165:1722-1730.
    PubMed     Abstract available
    
    
    
81. KONSTANTINOV IE
    External support for carinal stabilization: Follow-up from infancy to adolescence.
    J Thorac Cardiovasc Surg. 2023;165:e206-e207.
    PubMed    
    
    
    
82. NELSON DB, Mehran RJ, Mena GE, Hofstetter WL, et al
    Enhanced recovery after surgery improves postdischarge recovery after pulmonary lobectomy.
    J Thorac Cardiovasc Surg. 2023;165:1731-1740.
    PubMed     Abstract available
    
    
    April 2023
83. KUMAR A, Kumar S, Potter AL, Raman V, et al
    Surgical Management of Non-small-cell Lung Cancer with Limited Metastatic Disease Involving Only the Brain.
    J Thorac Cardiovasc Surg. 2023 Apr 28:S0022-5223(23)00358.
    PubMed     Abstract available
    
    
    
84. DEBOEVER N, Correa A, Feldman H, Mathur U, et al
    Disparities in early-stage lung cancer outcomes at minority serving hospitals compared to non-minority serving hospitals.
    J Thorac Cardiovasc Surg. 2023 Apr 26:S0022-5223(23)00349.
    PubMed     Abstract available
    
    
    
85. CARR SR, Wang H, Hudlikar R, Lu X, et al
    A Unique Gene Signature Predicting Recurrence Free Survival in Stage IA Lung Adenocarcinoma.
    J Thorac Cardiovasc Surg. 2023;165:1554-1564.
    PubMed     Abstract available
    
    
    March 2023
86. LI X, Li Q, Yang F, Gao E, et al
    Neoadjuvant therapy does not increase postoperative morbidity of sleeve lobectomy in locally advanced non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2023 Mar 23:S0022-5223(23)00254.
    PubMed     Abstract available
    
    
    
87. VANSTRAELEN S, Jones DR, Rocco G
    Breathprinting analysis and biomimetic sensor technology to detect lung cancer.
    J Thorac Cardiovasc Surg. 2023 Mar 9:S0022-5223(23)00190.
    PubMed    
    
    
    
88. SEITLINGER J, Spicer JD
    Turning the tides on the perioperative care of resectable lung cancer.
    J Thorac Cardiovasc Surg. 2023 Mar 3:S0022-5223(23)00184.
    PubMed    
    
    
    
89. SHARGALL Y, Wiercioch W, Brunelli A, Murthy S, et al
    Joint 2022 European Society of Thoracic Surgeons and The American Association for Thoracic Surgery guidelines for the prevention of cancer-associated venous thromboembolism in thoracic surgery.
    J Thorac Cardiovasc Surg. 2023;165:794-824.
    PubMed     Abstract available
    
    
    
90. D'AMICO TA
    Japanese Oncology Group 0802: Another giant leap.
    J Thorac Cardiovasc Surg. 2023;165:873-875.
    PubMed    
    
    
    
91. CHEN Z, Bernards N, Gregor A, Vannelli C, et al
    Anatomic evaluation of Pancoast tumors using three-dimensional models for surgical strategy development.
    J Thorac Cardiovasc Surg. 2023;165:842-852.
    PubMed     Abstract available
    
    
    
92. INRA ML, Wasserman GA, Karp J, Cohen S, et al
    Improvement in postoperative lung function in patients with moderate to severe airway obstruction after robotic-assisted thoracoscopic tracheobronchoplasty.
    J Thorac Cardiovasc Surg. 2023;165:876-885.
    PubMed     Abstract available
    
    
    
93. ZHOU D, Gao Y, Wang H, Xin H, et al
    Prevalence and anatomical characteristics of subsuperior segment in lung lower lobe.
    J Thorac Cardiovasc Surg. 2023;165:864-872.
    PubMed     Abstract available
    
    
    
94. PEREZ HOLGUIN RA, Olecki EJ, Wong WG, Stahl KA, et al
    Outcomes after sublobar resection versus lobectomy in non-small cell carcinoma in situ.
    J Thorac Cardiovasc Surg. 2023;165:853-861.
    PubMed     Abstract available
    
    
    
95. BERTOLACCINI L, Spaggiari L
    Commentary: The sublobar resections and the difference between a conjecture and a theorem.
    J Thorac Cardiovasc Surg. 2023;165:862-863.
    PubMed    
    
    
    February 2023
96. WHITHAM T, Wima K, Harnett B, Kues JR, et al
    Lung cancer screening utilization rate varies based on patient, provider, and hospital factors.
    J Thorac Cardiovasc Surg. 2023 Feb 21:S0022-5223(23)00172.
    PubMed     Abstract available
    
    
    
97. COOLEY-RIEDERS K, Glenn C, Van Haren RM, Salfity H, et al
    A decade of surgical outcomes in a structured lung cancer screening program.
    J Thorac Cardiovasc Surg. 2023 Feb 4:S0022-5223(23)00097.
    PubMed     Abstract available
    
    
    
98. GAUTHIER JM, Kozower BD
    Commentary: Stereotactic body radiation therapy utilization emits answers to the volume-outcome relationship.
    J Thorac Cardiovasc Surg. 2023;165:480-481.
    PubMed    
    
    
    January 2023
99. KENNEDY GT, Azari FS, Chang A, Nadeem B, et al
    Single-institution experience of 500 pulmonary resections guided by intraoperative molecular imaging.
    J Thorac Cardiovasc Surg. 2023 Jan 30:S0022-5223(23)00093.
    PubMed     Abstract available
    
    
    
100. LEE JM, Vallieres E, Ding B, Johnson A, et al
     Safety of adjuvant atezolizumab after pneumonectomy/bilobectomy in stage II-IIIA non-small cell lung cancer in the randomized phase III IMpower010 trial.
     J Thorac Cardiovasc Surg. 2023 Jan 21:S0022-5223(23)00080.
     PubMed     Abstract available
     
     
     
101. LANUTI M
     Commentary: Evolution of the preoperative space: Neoadjuvant targeted therapy in patients with operable non-small cell lung cancer with actionable mutations ... Surgeon equipoise?
     J Thorac Cardiovasc Surg. 2023 Jan 7:S0022-5223(23)00005.
     PubMed    
     
     
     
102. GILES AE, Cassivi SD
     Commentary: Lest we biopsy: Positron emission tomography-computed tomography as a tool to achieve a "greater good" in the diagnosis and management of the resectable anterior mediastinal mass.
     J Thorac Cardiovasc Surg. 2023;165:382-383.
     PubMed    
     
     
     
103. RIPLEY RT, Mansfield AS, Sepesi B, Bueno R, et al
     Checkpoint blockade in unresectable pleural mesothelioma: Event horizon for multimodal therapy.
     J Thorac Cardiovasc Surg. 2023;165:364-368.
     PubMed    
     
     
     December 2022
104. MARMOR HN, Kammer MN, Deppen SA, Shipe M, et al
     Improving lung cancer diagnosis with cancer, fungal, and imaging biomarkers.
     J Thorac Cardiovasc Surg. 2022 Dec 23:S0022-5223(22)01354.
     PubMed     Abstract available
     
     
     
105. MATHEY-ANDREWS C, McCarthy M, Potter AL, Beqari J, et al
     Safety and feasibility of minimally invasive lobectomy after neoadjuvant immunotherapy for non-small cell lung cancer.
     J Thorac Cardiovasc Surg. 2022 Dec 16:S0022-5223(22)01342.
     PubMed     Abstract available
     
     
     
106. DUAN X, Yang Z, Hao X, Zhou S, et al
     Early ligation of the pulmonary vein can reduce the dissemination of shed tumor cells during thoracoscopic lobectomy.
     J Thorac Cardiovasc Surg. 2022;164:1623-1635.
     PubMed     Abstract available
     
     
     November 2022
107. LENGEL HB, Zheng J, Tan KS, Liu CC, et al
     Clinicopathologic outcomes of preoperative targeted therapy in patients with clinical stage I to III non-small cell lung cancer.
     J Thorac Cardiovasc Surg. 2022 Nov 17:S0022-5223(22)01246.
     PubMed     Abstract available
     
     
     
108. BROWNLEE AR, Soukiasian HJ
     Commentary: Minimally invasive lobectomy for lung cancer: Safely finishing what you started.
     J Thorac Cardiovasc Surg. 2022 Nov 12:S0022-5223(22)01237.
     PubMed    
     
     
     
109. ERWIN P, Donington J
     Oncologic end points and implication of trial design in the era of immunotherapy for resectable non-small cell lung cancer.
     J Thorac Cardiovasc Surg. 2022 Nov 4:S0022-5223(22)01170.
     PubMed    
     
     
     
110. TSITSIAS T, Yasufuku K, Pierre A, Leighl N, et al
     Influence of anterior tumor location on survival after resection of lung cancer invading the thoracic inlet (Pancoast tumors).
     J Thorac Cardiovasc Surg. 2022 Nov 2:S0022-5223(22)01154.
     PubMed     Abstract available
     
     
     
111. LAPIDOT M, Mazzola E, Bueno R
     Outcomes of pleurectomy decortication in patients with biphasic mesothelioma.
     J Thorac Cardiovasc Surg. 2022;164:1340-1348.
     PubMed     Abstract available
     
     
     
112. FRIEDBERG JS
     Commentary: "Can we" versus "should we": The defining dilemma of mesothelioma surgery.
     J Thorac Cardiovasc Surg. 2022;164:1349-1350.
     PubMed    
     
     
     
113. TSUTANI Y, Ito M, Shimada Y, Ito H, et al
     The impact of epidermal growth factor receptor mutation status on adjuvant chemotherapy for patients with high-risk stage I lung adenocarcinoma.
     J Thorac Cardiovasc Surg. 2022;164:1306-1315.
     PubMed     Abstract available
     
     
     October 2022
114. ALTORKI NK, Villena-Vargas J
     Commentary: Neoadjuvant immune checkpoint monotherapy for lung cancer: Has the train left the station?
     J Thorac Cardiovasc Surg. 2022 Oct 30:S0022-5223(22)01152.
     PubMed    
     
     
     
115. KALATA S, Lam GT, Alnajjar RM, Clark MJ, et al
     Adequate lung cancer surgery lymphadenectomy within a statewide quality collaborative: Quality improvement in action.
     J Thorac Cardiovasc Surg. 2022 Oct 28:S0022-5223(22)01150.
     PubMed     Abstract available
     
     
     
116. PREDINA J, Suliman R, Potter AL, Panda N, et al
     Postoperative radiotherapy with modern techniques does not improve survival for operable stage IIIA-N2 non-small cell lung cancer.
     J Thorac Cardiovasc Surg. 2022 Oct 18:S0022-5223(22)01134.
     PubMed     Abstract available
     
     
     
117. RUSCH VW, Nicholas A, Patterson GA, Waqar SN, et al
     Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non-small cell lun
     J Thorac Cardiovasc Surg. 2022 Oct 8. pii: S0022-5223(22)01055.
     PubMed     Abstract available
     
     
     September 2022
118. SAKOWITZ S, Verma A, Mabeza RM, Cho NY, et al
     Clinical and financial outcomes of pulmonary resection for lung cancer in safety-net hospitals.
     J Thorac Cardiovasc Surg. 2022 Sep 27. pii: S0022-5223(22)01026.
     PubMed     Abstract available
     
     
     
119. QIU B, Ji Y, Zhang F, Bai G, et al
     Outcomes and experience of anatomical partial lobectomy.
     J Thorac Cardiovasc Surg. 2022;164:637-647.
     PubMed     Abstract available
     
     
     
120. ZHANG Y, Chen H
     Commentary: Anatomical partial lobectomy: The indications should be better defined.
     J Thorac Cardiovasc Surg. 2022;164:648-649.
     PubMed    
     
     
     August 2022
121. HASHIMOTO K, Ariyasu R, Ichinose J, Matsuura Y, et al
     Advances in the treatment of postoperative recurrence of non-small cell lung cancer and their impact on survival in Asian patients.
     J Thorac Cardiovasc Surg. 2022 Aug 25. pii: S0022-5223(22)00903.
     PubMed     Abstract available
     
     
     
122. LEE B, Mynard N, Nasar A, Villena-Vargas J, et al
     Surgical resection after neoadjuvant durvalumab and radiation is feasible and safe in non-small cell lung cancer: Results from a randomized trial.
     J Thorac Cardiovasc Surg. 2022 Aug 6. pii: S0022-5223(22)00804.
     PubMed     Abstract available
     
     
     
123. TILL BM, Mack S, Whitehorn G, Rahman U, et al
     Impact of stereotactic body radiation therapy volume on surgical patient selection, short-term survival, and long-term survival in early-stage non-small cell lung cancer.
     J Thorac Cardiovasc Surg. 2022 Aug 6. pii: S0022-5223(22)00816.
     PubMed     Abstract available
     
     
     
124. LOGAN CD, Jacobs RC, Feinglass J, Lung K, et al
     National trends in the quality of segmentectomy for lung cancer.
     J Thorac Cardiovasc Surg. 2022 Aug 5. pii: S0022-5223(22)00821.
     PubMed     Abstract available
     
     
     
125. LEE JM
     Commentary: The search for a chemotherapy-free immunotherapy regimen in resectable non-small cell lung cancer: The unmet need.
     J Thorac Cardiovasc Surg. 2022 Aug 3. pii: S0022-5223(22)00807.
     PubMed    
     
     
     
126. DELMAN AM, Turner KM, Wima K, Simon VE, et al
     Offering lung resection to current smokers: An opportunity for more equitable care.
     J Thorac Cardiovasc Surg. 2022;164:400-408.
     PubMed     Abstract available
     
     
     July 2022
127. KHO J, Mitchell J, Curry N, Di Chiara F, et al
     Should all patients receive extended thromboprophylaxis after resection of primary lung cancer?
     J Thorac Cardiovasc Surg. 2022 Jul 5. pii: S0022-5223(22)00712.
     PubMed     Abstract available
     
     
     
128. LI D, Deng C, Wang S, Li Y, et al
     Ten-year follow-up of lung cancer patients with resected adenocarcinoma in situ or minimally invasive adenocarcinoma: Wedge resection is curative.
     J Thorac Cardiovasc Surg. 2022 Jul 5. pii: S0022-5223(22)00713.
     PubMed     Abstract available
     
     
     
129. SULLIVAN KA, Farrokhyar F, Leontiadis GI, Patel YS, et al
     Routine systematic sampling versus targeted sampling during endobronchial ultrasound: A randomized feasibility trial.
     J Thorac Cardiovasc Surg. 2022;164:254-261.
     PubMed     Abstract available
     
     
     
130. LIN J
     Commentary: Teach me to fish-spears, rods, and nets: Lymph node sampling during endobronchial ultrasound.
     J Thorac Cardiovasc Surg. 2022;164:263-264.
     PubMed    
     
     
     
131. NA KJ, Kim YT
     Commentary: Targeted sampling during endobronchial ultrasound: Additional prerequisites for clinical implementation.
     J Thorac Cardiovasc Surg. 2022;164:262-263.
     PubMed    
     
     
     
132. SATO M, Kobayashi M, Sakamoto J, Fukai R, et al
     The role of virtual-assisted lung mapping 2.0 combining microcoils and dye marks in deep lung resection.
     J Thorac Cardiovasc Surg. 2022;164:243-251.
     PubMed     Abstract available
     
     
     June 2022
133. RUSCH VW
     Commentary: Surgical standardization in mesothelioma trials.
     J Thorac Cardiovasc Surg. 2022;163:1949-1950.
     PubMed    
     
     
     
134. GIFFIN C, Kidane B
     Commentary: Less is maybe more: Sublobar resection in screen-detected lung cancers.
     J Thorac Cardiovasc Surg. 2022;163:1917-1918.
     PubMed    
     
     
     
135. HASEGAWA S, Yokoi K, Okada M, Tanaka F, et al
     Neoadjuvant pemetrexed plus cisplatin followed by pleurectomy for malignant pleural mesothelioma.
     J Thorac Cardiovasc Surg. 2022;163:1940-1947.
     PubMed     Abstract available
     
     
     
136. GRIFFIN CM, van Berkel VH
     Commentary: A return trip to MARS: Less may be more when treating mesothelioma.
     J Thorac Cardiovasc Surg. 2022;163:1948-1949.
     PubMed    
     
     
     May 2022
137. LIN J
     Commentary: Maximum standardized uptake value is no crystal ball for candidate selection for sublobar resection: The future is cloudy (ground-glass).
     J Thorac Cardiovasc Surg. 2022;163:1667-1668.
     PubMed    
     
     
     
138. GILES AE, Kidane B
     Commentary: Toward precision surgery: Advances in defining sublobar resection candidacy.
     J Thorac Cardiovasc Surg. 2022;163:1666-1667.
     PubMed    
     
     
     
139. MURAOKA Y, Yoshida Y, Nakagawa K, Ito K, et al
     Maximum standardized uptake value of the primary tumor does not improve candidate selection for sublobar resection.
     J Thorac Cardiovasc Surg. 2022;163:1656-1665.
     PubMed     Abstract available
     
     
     
140. ABDALLAH HM, Martinez-Meehan D, Lutfi W, Dhupar R, et al
     Adjuvant chemotherapy for pulmonary sarcomatoid carcinoma: A retrospective analysis of the National Cancer Database.
     J Thorac Cardiovasc Surg. 2022;163:1669-1681.
     PubMed     Abstract available
     
     
     April 2022
141. FURRER K, Weder W, Eboulet EI, Betticher D, et al
     Extended resection for potentially operable patients with stage III non-small cell lung cancer after induction treatment.
     J Thorac Cardiovasc Surg. 2022 Apr 18. pii: S0022-5223(22)00403.
     PubMed     Abstract available
     
     
     
142. THOMAS PA
     Commentary: Challenging the final frontier of lung transplantation.
     J Thorac Cardiovasc Surg. 2022 Apr 9. pii: S0022-5223(22)00400.
     PubMed    
     
     
     
143. STARNES SL
     Commentary: Artificial intelligence for pulmonary nodules: Machines to diagnosis cancer.
     J Thorac Cardiovasc Surg. 2022;163:1506-1507.
     PubMed    
     
     
     
144. ASHRAF SF, Yin K, Meng CX, Wang Q, et al
     Predicting benign, preinvasive, and invasive lung nodules on computed tomography scans using machine learning.
     J Thorac Cardiovasc Surg. 2022;163:1496-1505.
     PubMed     Abstract available
     
     
     
145. KNEUERTZ PJ, Yudovich MS, Amadi CC, Bashian E, et al
     Pulmonary artery size on computed tomography is associated with major morbidity after pulmonary lobectomy.
     J Thorac Cardiovasc Surg. 2022;163:1521-1529.
     PubMed     Abstract available
     
     
     
146. EKEKE CN, Russell KL, Murthy P, Guo ZS, et al
     Intrapleural interleukin-2-expressing oncolytic virotherapy enhances acute antitumor effects and T-cell receptor diversity in malignant pleural disease.
     J Thorac Cardiovasc Surg. 2022;163:e313-e328.
     PubMed     Abstract available
     
     
     March 2022
147. ISHIWATA T, Motooka Y, Ujiie H, Inage T, et al
     Endobronchial ultrasound-guided bipolar radiofrequency ablation for lung cancer: A first-in-human clinical trial.
     J Thorac Cardiovasc Surg. 2022 Mar 26. pii: S0022-5223(22)00344.
     PubMed     Abstract available
     
     
     
148. CHIDI AP, Broderick SR
     Commentary: Perioperative systemic therapy in early-stage non-small cell lung cancer: The future is bright.
     J Thorac Cardiovasc Surg. 2022 Mar 24. pii: S0022-5223(22)00345.
     PubMed    
     
     
     
149. HEIDEN BT, Subramanian MP, Liu J, Keith A, et al
     Long-term patient-reported outcomes after non-small cell lung cancer resection.
     J Thorac Cardiovasc Surg. 2022 Mar 12. pii: S0022-5223(22)00270.
     PubMed     Abstract available
     
     
     
150. ELKIN PL, Mullin S, Tetewsky S, Resendez SD, et al
     Identification of patient characteristics associated with survival benefit from metformin treatment in patients with stage I non-small cell lung cancer.
     J Thorac Cardiovasc Surg. 2022 Mar 10. pii: S0022-5223(22)00241.
     PubMed     Abstract available
     
     
     
151. LIN J
     Commentary: Reading the voxels: A fortune teller's nomogram to invasiveness in stage IA lung adenocarcinoma.
     J Thorac Cardiovasc Surg. 2022;163:816-817.
     PubMed    
     
     
     
152. BRUNELLI A
     Commentary: Ground glass opacity: Is it the Holy Grail?
     J Thorac Cardiovasc Surg. 2022;163:802-803.
     PubMed    
     
     
     
153. QIU ZB, Zhang C, Chu XP, Cai FY, et al
     Quantifying invasiveness of clinical stage IA lung adenocarcinoma with computed tomography texture features.
     J Thorac Cardiovasc Surg. 2022;163:805-815.
     PubMed     Abstract available
     
     
     
154. VILLENA-VARGAS J, Lutton EM, Mynard N, Nasar A, et al
     Safety of lung cancer surgery during COVID-19 in a pandemic epicenter.
     J Thorac Cardiovasc Surg. 2022 Mar 1. pii: S0022-5223(22)00222.
     PubMed     Abstract available
     
     
     February 2022
155. ALTORKI N, Villena-Vargas J, Wakelee H
     Adjuvant therapy for early-stage non-small cell lung cancer: The breaking of a new dawn.
     J Thorac Cardiovasc Surg. 2022 Feb 17. pii: S0022-5223(22)00202.
     PubMed    
     
     
     
156. CASTRO PP, de Perrot M, Chua YC, Bezjak A, et al
     Importance of tumor size in resectable stage III-N2 non-small cell lung cancer.
     J Thorac Cardiovasc Surg. 2022 Feb 11. pii: S0022-5223(22)00195.
     PubMed     Abstract available
     
     
     
157. STILES BM
     Commentary: Early stage epidermal growth factor receptor lung cancer: Skip to the good stuff?
     J Thorac Cardiovasc Surg. 2022 Feb 5. pii: S0022-5223(22)00125.
     PubMed    
     
     
     
158. GRAY KD, Molena D
     Commentary: To cut is a chance to cure? Lessons to be learned from the PulMiCC trial.
     J Thorac Cardiovasc Surg. 2022;163:493-494.
     PubMed    
     
     
     
159. VAN RAEMDONCK D, Van Cutsem E
     Commentary: A crusade against current pulmonary metastasectomy practice in colorectal cancer patients: Do the con arguments remain after the PulMiCC trial?
     J Thorac Cardiovasc Surg. 2022;163:491-492.
     PubMed    
     
     
     
160. ALTORKI N, Vimolratana M
     Commentary: Surgery for ground-glass nodules: Free lunch or slippery slope?
     J Thorac Cardiovasc Surg. 2022;163:465-466.
     PubMed    
     
     
     
161. PASS HI
     Commentary: Pulmonary metastasectomy efficacy: A game of clones?
     J Thorac Cardiovasc Surg. 2022;163:503-510.
     PubMed    
     
     
     
162. BLUMENTHALER AN, Antonoff MB
     Commentary: The best outcomes for pulmonary metastasectomy come from picking the right patients.
     J Thorac Cardiovasc Surg. 2022;163:483-484.
     PubMed    
     
     
     
163. TREASURE T, Dunning J, Williams NR, Macbeth F, et al
     Lung metastasectomy for colorectal cancer: The impression of benefit from uncontrolled studies was not supported in a randomized controlled trial.
     J Thorac Cardiovasc Surg. 2022;163:486-490.
     PubMed    
     
     
     
164. ZHANG Y, Ma X, Shen X, Wang S, et al
     Surgery for pre- and minimally invasive lung adenocarcinoma.
     J Thorac Cardiovasc Surg. 2022;163:456-464.
     PubMed     Abstract available
     
     
     
165. LIU Z, Yin J, Zhou Q, Yang J, et al
     Survival after pulmonary metastasectomy for relapsed osteosarcoma.
     J Thorac Cardiovasc Surg. 2022;163:469-479.
     PubMed     Abstract available
     
     
     
166. MATSUURA Y, Ninomiya H, Ichinose J, Nakao M, et al
     Prognostic impact and distinctive characteristics of surgically resected anaplastic lymphoma kinase-rearranged lung adenocarcinoma.
     J Thorac Cardiovasc Surg. 2022;163:441-451.
     PubMed     Abstract available
     
     
     January 2022
167. SEPESI B, Zhou N, William WN Jr, Lin HY, et al
     Surgical outcomes after nivolumab or nivolumab with ipilimumab treatment in patients with non-small cell lung cancer.
     J Thorac Cardiovasc Surg. 2022 Jan 23. pii: S0022-5223(22)00089.
     PubMed     Abstract available
     
     
     
168. WATANABE I, Hattori A, Fukui M, Matsunaga T, et al
     Pulmonary artery reconstruction for non-small cell lung cancer: Surgical management and long-term outcomes.
     J Thorac Cardiovasc Surg. 2022 Jan 22. pii: S0022-5223(22)00087.
     PubMed     Abstract available
     
     
     
169. LANUTI M
     Commentary: Induction antiangiogenesis for stage IIIA-N2 non-small cell lung cancer is not the answer yet: Optimal induction for operable disease is a clear work in progress.
     J Thorac Cardiovasc Surg. 2022 Jan 8. pii: S0022-5223(22)00007.
     PubMed    
     
     
     
170. LAZAR JF, Herrera LJ
     Commentary: Ablation and endobronchial ultrasound for treating early lung cancer: Two great technologies that may work great together!
     J Thorac Cardiovasc Surg. 2022 Jan 8. pii: S0022-5223(22)00009.
     PubMed    
     
     
     
171. LINDEN PA
     Commentary: Spread the news: Spread through air spaces matters.
     J Thorac Cardiovasc Surg. 2022;163:285.
     PubMed    
     
     
     
172. LIN J
     Commentary: Should we start spreading the news? Prognostic influence of spread through air spaces in early-stage lung adenocarcinoma.
     J Thorac Cardiovasc Surg. 2022;163:286-287.
     PubMed    
     
     
     
173. DAVID EA
     Commentary: STAS is here to STAY.
     J Thorac Cardiovasc Surg. 2022;163:287-288.
     PubMed    
     
     
     
174. ZHANG Y, Chen H
     Commentary: Is sublobar resection enough for ground-glass opacity-dominant lung adenocarcinoma?
     J Thorac Cardiovasc Surg. 2022;163:303-304.
     PubMed    
     
     
     
175. ZHANG Y, Cao Y, Li H
     REPLY: THE CONTINUED DEBATE ON ROBOTIC SEGMENTECTOMY-AGREE TO DISAGREE.
     J Thorac Cardiovasc Surg. 2022;163:e99-e100.
     PubMed    
     
     
     
176. JUNG W, Chung JH, Yum S, Kim K, et al
     The differential prognostic impact of spread through air spaces in early-stage lung adenocarcinoma after lobectomy according to the pT descriptor.
     J Thorac Cardiovasc Surg. 2022;163:277-284.
     PubMed     Abstract available
     
     
     
177. CORSINI EM, Ripley RT
     Commentary: KRAS-mutant lung adenocarcinomas-a work in progress.
     J Thorac Cardiovasc Surg. 2022;163:e87-e88.
     PubMed    
     
     
     
178. MA Z, Zhang Y, Deng C, Fu F, et al
     The prognostic value of Kirsten rat sarcoma viral oncogene homolog mutations in resected lung adenocarcinoma differs according to clinical features.
     J Thorac Cardiovasc Surg. 2022;163:e73-e85.
     PubMed     Abstract available
     
     
     December 2021
179. CONNOLLY JG, Fiasconaro M, Tan KS, Cirelli MA Jr, et al
     Postinduction therapy pulmonary function retesting is necessary before surgical resection for non-small cell lung cancer.
     J Thorac Cardiovasc Surg. 2021 Dec 23. pii: S0022-5223(21)01818.
     PubMed     Abstract available
     
     
     
180. TAKAMOCHI K, Suzuki K, Tsuboi M, Niho S, et al
     Randomized phase II trial of pemetrexed-cisplatin plus bevacizumab or thoracic radiotherapy followed by surgery for stage IIIA (N2) nonsquamous non-small cell lung cancer.
     J Thorac Cardiovasc Surg. 2021 Dec 9. pii: S0022-5223(21)01714.
     PubMed     Abstract available
     
     
     
181. SAVITCH SL, Grenda TR, Yi M, Till B, et al
     Facility-level national trends in racial disparities of surgical therapy for early-stage lung cancer.
     J Thorac Cardiovasc Surg. 2021 Dec 9. pii: S0022-5223(21)01716.
     PubMed     Abstract available
     
     
     
182. ARNOLD BN, Antonoff MB
     Commentary: Optimizing resources in lung cancer survivorship.
     J Thorac Cardiovasc Surg. 2021 Dec 4. pii: S0022-5223(21)01691.
     PubMed    
     
     
     
183. CHEN J, Soultanis KM, Sun F, Gonzalez-Rivas D, et al
     Outcomes of sleeve lobectomy versus pneumonectomy: A propensity score-matched study.
     J Thorac Cardiovasc Surg. 2021;162:1619-1628.
     PubMed     Abstract available
     
     
     November 2021
184. SHENOY R, Okereke I
     Commentary: Lung cancer resections during the pandemic.
     J Thorac Cardiovasc Surg. 2021 Nov 20. pii: S0022-5223(21)01651.
     PubMed    
     
     
     
185. CHANG SH
     Commentary: Surgery versus stereotactic body radiation therapy for patients with renal dysfunction and non-small cell lung cancer: The answer is still not clear.
     J Thorac Cardiovasc Surg. 2021 Nov 20. pii: S0022-5223(21)01647.
     PubMed    
     
     
     
186. KESHAVA HB, Tan KS, Dycoco J, Huang J, et al
     Long-term assessment of efficacy with a novel thoracic survivorship program for patients with lung cancer.
     J Thorac Cardiovasc Surg. 2021 Nov 20. pii: S0022-5223(21)01635.
     PubMed     Abstract available
     
     
     October 2021
187. POULSON MR, Kenzik KM, Singh S, Pavesi F, et al
     Redlining, structural racism, and lung cancer screening disparities.
     J Thorac Cardiovasc Surg. 2021 Oct 14. pii: S0022-5223(21)01421.
     PubMed     Abstract available
     
     
     
188. HANNA WC
     Commentary: Wedge versus segmentectomy-It is best to err on the side of caution.
     J Thorac Cardiovasc Surg. 2021;162:1254.
     PubMed    
     
     
     September 2021
189. DELMAN AM, Van Haren RM
     Commentary: Mitigating lung cancer mortality in patients with end-stage renal disease.
     J Thorac Cardiovasc Surg. 2021 Sep 27. pii: S0022-5223(21)01389.
     PubMed    
     
     
     
190. SAITO T, Murakawa T, Shintani Y, Okami J, et al
     Preoperative renal dysfunction and long-term survival after surgery for non-small cell lung cancer.
     J Thorac Cardiovasc Surg. 2021 Sep 10. pii: S0022-5223(21)01311.
     PubMed     Abstract available
     
     
     
191. FARMER DM, Ripley RT
     Commentary: EGFR mutations lung adenocarcinoma-Is the driver removed with the lobe?
     J Thorac Cardiovasc Surg. 2021;162:675-676.
     PubMed    
     
     
     
192. KHORFAN R, Cooke DT, Meguid RA, Backhus L, et al
     Institutional factors associated with adherence to quality measures for stage I and II non-small cell lung cancer.
     J Thorac Cardiovasc Surg. 2021;162:649-660.
     PubMed     Abstract available
     
     
     
193. DENG C, Zhang Y, Ma Z, Fu F, et al
     Prognostic value of epidermal growth factor receptor gene mutation in resected lung adenocarcinoma.
     J Thorac Cardiovasc Surg. 2021;162:664-674.
     PubMed     Abstract available
     
     
     August 2021
194. BRUNELLI A
     Commentary: Lobectomy should be the exception rather than the rule to resect screen-detected stage I non-small cell lung cancer.
     J Thorac Cardiovasc Surg. 2021 Aug 27. pii: S0022-5223(21)01253.
     PubMed    
     
     
     
195. EGYUD M, Burt BM
     Commentary: The structure of structural racism revealed by lung cancer screening.
     J Thorac Cardiovasc Surg. 2021 Aug 24. pii: S0022-5223(21)01248.
     PubMed    
     
     
     
196. SIENICKI E, Onaitis M
     Commentary: New players in epidermal growth factor receptor tyrosine kinase inhibitor resistance.
     J Thorac Cardiovasc Surg. 2021;162:474-475.
     PubMed    
     
     
     
197. FU F, Zhang Y, Wang S, Li Y, et al
     Computed tomography density is not associated with pathological tumor invasion for pure ground-glass nodules.
     J Thorac Cardiovasc Surg. 2021;162:451-459.
     PubMed     Abstract available
     
     
     
198. YOSHIYASU N, Kojima F, Hayashi K, Bando T, et al
     Radiomics technology for identifying early-stage lung adenocarcinomas suitable for sublobar resection.
     J Thorac Cardiovasc Surg. 2021;162:477-485.
     PubMed     Abstract available
     
     
     July 2021
199. PENNATHUR A, Brunelli A, Criner G, Keshavarz H, et al
     Definition and assessment of high risk in patients considered for lobectomy for stage I non-small cell lung cancer: The American Association for Thoracic Surgery expert panel consensus document.
     J Thorac Cardiovasc Surg. 2021 Jul 29. pii: S0022-5223(21)01129.
     PubMed     Abstract available
     
     
     
200. CHUDGAR NP, Stiles BM
     Commentary: Adjuvant therapy in resected T1 2N0 non-small cell lung cancer: Surgeons should lead.
     J Thorac Cardiovasc Surg. 2021 Jul 14. pii: S0022-5223(21)01036.
     PubMed    
     
     
     
201. WOODARD GA, Li A, Boffa DJ
     Role of adjuvant therapy in T1-2N0 resected non-small cell lung cancer.
     J Thorac Cardiovasc Surg. 2021 Jul 10. pii: S0022-5223(21)01032.
     PubMed    
     
     
     
202. WANG SX, Marshall MB
     Commentary: A new hope: Do ADAURA trial results change the paradigm for treatment of resectable lung adenocarcinoma?
     J Thorac Cardiovasc Surg. 2021;162:293-294.
     PubMed    
     
     
     
203. ANTONOFF MB, Morris VK
     Reply from author: Biology is king, but metastasectomy still has a role for properly selected patients.
     J Thorac Cardiovasc Surg. 2021;162:e136-e138.
     PubMed    
     
     
     
204. CAMERON RB
     Reply: Discussions regarding pulmonary metastasectomy are similar to American politics: Both are extremely polarizing, unsatisfying, inconclusive, and undertaken at your own peril.
     J Thorac Cardiovasc Surg. 2021;162:e135-e136.
     PubMed    
     
     
     
205. HIRPARA DH, Kidane B
     Commentary: VATS, RATS, stats, and some caveats.
     J Thorac Cardiovasc Surg. 2021;162:269-270.
     PubMed    
     
     
     
206. SIHAG S
     Commentary: Sarcomas and sarcomatoid tumors of the lung...not your average lung cancers.
     J Thorac Cardiovasc Surg. 2021;162:285-286.
     PubMed    
     
     
     
207. JONES DR, Wu YL, Tsuboi M, Herbst RS, et al
     Targeted therapies for resectable lung adenocarcinoma: ADAURA opens for thoracic oncologic surgeons.
     J Thorac Cardiovasc Surg. 2021;162:288-292.
     PubMed    
     
     
     
208. CORSINI EM, Mitchell KG, Correa A, Morris VK, et al
     Effect of primary colorectal cancer tumor location on survival after pulmonary metastasectomy.
     J Thorac Cardiovasc Surg. 2021;162:296-305.
     PubMed     Abstract available
     
     
     
209. ROBINSON LA, Babacan NA, Tanvetyanon T, Henderson-Jackson E, et al
     Results of treating primary pulmonary sarcomas and pulmonary carcinosarcomas.
     J Thorac Cardiovasc Surg. 2021;162:274-284.
     PubMed     Abstract available
     
     
     
210. KAMEL MK, Lee B, Harrison SW, Port JL, et al
     Sublobar resection is comparable to lobectomy for screen-detected lung cancer.
     J Thorac Cardiovasc Surg. 2021 Jul 1. pii: S0022-5223(21)01011.
     PubMed     Abstract available
     
     
     May 2021
211. ISBELL JM, Li BT, Gomez DR
     The emerging role of local therapy in oligometastatic non-small cell lung cancer.
     J Thorac Cardiovasc Surg. 2021 May 29. pii: S0022-5223(21)00875.
     PubMed    
     
     
     
212. DONINGTON JS
     Commentary: Why do we operate in metastatic lung cancer?
     J Thorac Cardiovasc Surg. 2021 May 8. pii: S0022-5223(21)00771.
     PubMed    
     
     
     
213. WIGHTMAN SC, Kim AW
     Commentary: When less is more for lung cancers.
     J Thorac Cardiovasc Surg. 2021;161:1650-1651.
     PubMed    
     
     
     
214. CERFOLIO RJ
     Commentary: Let us raise the bar higher for better patient outcomes.
     J Thorac Cardiovasc Surg. 2021;161:1649-1650.
     PubMed    
     
     
     
215. WEKSLER B, Sullivan JL, Schumacher LY
     Randomized trial of bupivacaine with epinephrine versus bupivacaine liposome suspension in patients undergoing minimally invasive lung resection.
     J Thorac Cardiovasc Surg. 2021;161:1652-1661.
     PubMed     Abstract available
     
     
     April 2021
216. FERNANDEZ R, Ahmad U
     Commentary: A new hope-neoadjuvant immunotherapy for resectable non-small cell lung cancer.
     J Thorac Cardiovasc Surg. 2021 Apr 27. pii: S0022-5223(21)00740.
     PubMed    
     
     
     
217. BONNER SN, Wakeam E
     The volume-outcome relationship in lung cancer surgery: The impact of the social determinants of health care delivery.
     J Thorac Cardiovasc Surg. 2021 Apr 20. pii: S0022-5223(21)00593.
     PubMed    
     
     
     
218. TONG BC, Gu L, Wang X, Wigle DA, et al
     Perioperative outcomes of pulmonary resection after neoadjuvant pembrolizumab in patients with non-small cell lung cancer.
     J Thorac Cardiovasc Surg. 2021 Apr 9. pii: S0022-5223(21)00583.
     PubMed     Abstract available
     
     
     
219. HOD T, Freedberg KJ, Motwani SS, Chen M, et al
     Acute kidney injury after cytoreductive surgery and hyperthermic intraoperative cisplatin chemotherapy for malignant pleural mesothelioma.
     J Thorac Cardiovasc Surg. 2021;161:1510-1518.
     PubMed     Abstract available
     
     
     March 2021
220. ELY S, Jiang SF, Dominguez DA, Patel AR, et al
     Effect of thoracic surgery regionalization on long-term survival after lung cancer resection.
     J Thorac Cardiovasc Surg. 2021 Mar 20. pii: S0022-5223(21)00530.
     PubMed     Abstract available
     
     
     
221. ANTONOFF MB, Sofocleous CT, Callstrom MR, Nguyen QN, et al
     The roles of surgery, stereotactic radiation, and ablation for treatment of pulmonary metastases.
     J Thorac Cardiovasc Surg. 2021 Mar 6. pii: S0022-5223(21)00423.
     PubMed    
     
     
     
222. DONAHOE LL, Nason GJ, Bedard PL, Hansen AR, et al
     Pathologic concordance of resected metastatic nonseminomatous germ cell tumors in the chest.
     J Thorac Cardiovasc Surg. 2021;161:856-868.
     PubMed     Abstract available
     
     
     
223. SHEMANSKI KA, Farias A, Lieu D, Kim AW, et al
     Understanding thoracic surgeons' perceptions of administrative database analyses and guidelines in clinical decision-making.
     J Thorac Cardiovasc Surg. 2021;161:807-816.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.